Compass Pathways

Historical price data

Compass Pathways is a clinical-stage biotech company on a mission to accelerate patient access to evidence-based innovation in mental health. Its core strategy is the development of COMP360, a proprietary synthetic psilocybin, integrated with psychological support, currently in a global Phase 3 program for treatment-resistant depression (TRD). The company aims to establish a new paradigm in mental healthcare by addressing conditions where existing treatments are inadequate, leveraging rigorous science and a patient-centric approach.

Proprietary, high-purity synthetic psilocybin (COMP360) integrated with a standardized, psychologically supported therapeutic protocol and digital/training infrastructure.

Compass is a clinical leader in pharmaceutical-grade psilocybin development, with its main competition from public biotechs in earlier stages (e.g., Cybin, MindMed) and non-profit research institutes. Its competitive moat relies on regulatory exclusivity, protocol patents, and a vertically integrated delivery system.